What Is TB-500? Thymosin Beta-4 Fragment Explained

Written by Dr. Andrii Kaleniuk. Updated November 4, 2026.

TB-500 is a synthetic peptide fragment of thymosin beta-4: when an anti-doping laboratory in Ghent analysed a product sold as TB-500, the active ingredient was Ac-LKKTETQ, a chain of just seven amino acids copied from positions 17 to 23 of the natural protein, sold as a veterinary or 'research' product, never tested in humans, not approved by the FDA, and banned in sport by the World Anti-Doping Agency (WADA) under class S2. Thymosin beta-4 itself is a small protein your body makes naturally. Most healing claims for TB-500 come from animal studies of that full-length protein, and the human trials that exist also used the full protein, not TB-500, and mostly missed their main goals. As of November 2026, a draft US policy would let some pharmacies compound TB-500 under conditions, but that is not FDA approval. This guide covers what TB-500 is, the evidence, its legal and sporting status, and the safety unknowns.

Thymosin beta-4 is a 43-amino-acid protein, made from the TMSB4X gene and found in most cells. Its main job is to bind actin, the protein that forms the flexible scaffolding inside cells. By holding actin units in reserve, it helps cells reshape that scaffolding so they can move, which is why researchers studied it for wound healing: repair depends on cells migrating into damaged tissue.

The protein is also cut into smaller pieces in the body. One of these, a four-amino-acid fragment called Ac-SDKP from the very start of the chain, has anti-inflammatory and anti-scarring effects in lab studies. Ac-SDKP is not TB-500: it comes from positions 1 to 4, while TB-500 comes from positions 17 to 23.

No, although the names are often used as if they were. In 2012, the Ghent doping-control laboratory analysed a product sold online as TB-500 and labelled 'for veterinary use only'. It contained no intact thymosin beta-4. Instead, the active ingredient was Ac-LKKTETQ, the acetylated stretch of residues 17 to 23 that the authors described as the major actin-binding site of the protein. An equine doping-control paper the same year likewise called TB-500 a synthetic version of an active region of thymosin beta-4. Some labels and documents use 'TB-500' loosely, so a vial with that name may not contain what you expect.

TB-500 appeared as a product rather than as a medicine developed through clinical trials. The Ghent analysis found it sold with a veterinary-only label but also marketed online to anyone. Laboratories that test racehorses published a detection method for it in 2012, a sign that it was already on the radar of racing regulators. Today it is mostly sold as a 'research peptide', a label that sidesteps medical claims. It never went through drug testing, so there is no official information on purity or long-term effects.

Most of what people say TB-500 does comes from animal experiments using full-length thymosin beta-4, not the fragment:

Animal results often fail to carry over to people, and these do not show that the fragment sold as TB-500 does the same. We cover the muscle angle in more depth in TB-500 for muscle recovery.

No. We found no published human trial of TB-500 itself. The Ghent researchers noted that data on how it behaves in the body were lacking. What has been tested in humans is full-length thymosin beta-4, developed by the company RegeneRx, and the results are much weaker than marketing suggests:

A decade of human research on the parent protein produced, at best, modest effects on eye discomfort, and nothing on muscles, tendons or the heart.

Lifters usually take TB-500 for injury recovery, often with BPC-157 in the so-called Wolverine stack. How the claims hold up:

If you are comparing options, our guide to BPC-157 vs TB-500 sets out how thin the human evidence is for both, and BPC-157 for tendon recovery looks at the tendon claims specifically.

TB-500 is not approved by the FDA or any other regulator for human use. After an April 2026 notice, the FDA planned to remove it from its list of compounding substances with safety concerns and sent it to an advisory committee, which met on July 23, 2026. Law firm Frier Levitt notes that removal does not, by itself, allow compounding.

On October 28, 2026, the Department of Health and Human Services (HHS) announced a draft enforcement-discretion policy, published in the Federal Register on October 30. According to a summary by law firm Arnold & Porter, it covers TB-500, BPC-157 and several other peptides, and would let licensed 503A pharmacies compound them for individual patients under ten conditions, including a patient-specific prescription, ingredients from FDA-registered manufacturers, a single active ingredient and reporting of side effects. Comments are due November 13, 2026. AJMC reports that the policy does not grant FDA approval or establish clinical safety and effectiveness, and that FDA career staff recommended against listing these peptides. It is still a draft and does not make 'research peptide' websites legal sources.

The picture for BPC-157 is similar, as explained in is BPC-157 legal.

Yes. WADA's 2026 Prohibited List names 'thymosin-beta-4 and its derivatives, e.g. TB-500' in class S2 (peptide hormones, growth factors and related substances). It is banned in and out of competition, and national anti-doping agencies say therapeutic use exemptions are not available. Verified cases include:

Nobody knows the risks of TB-500 in people, because it has never been studied in them; the only human safety study used a different molecule. What we can say:

If an injury is driving your interest, start with a diagnosis, because a strain, a partial tear and tendinopathy are treated differently. Questions to ask:

For background on the peptide most often paired with TB-500, see what is BPC-157.

TB-500 is a short synthetic piece of thymosin beta-4 that has never been tested in humans. Its reputation rests on animal research with the full protein, whose human trials showed little beyond modest dry-eye effects. It is not FDA-approved; a draft HHS policy from October 2026 may open a narrow compounding route, but HHS itself says that is not approval. It is banned in sport, and its long-term safety, including any cancer risk, is unknown.

This article summarizes published research and regulatory information for general information only; it is not medical advice. The human trials of thymosin beta-4 cited here were sponsored by RegeneRx, the company developing it.